Cedric Tehranian1, Laura Fankhauser1, Patrick N Harter2,3,4, Colin D H Ratcliffe5, Pia S Zeiner2,6,4, Julia M Messmer1,7, Dirk C Hoffmann1,7, Katharina Frey1, Dana Westphal8, Michael W Ronellenfitsch6,4, Erik Sahai5, Wolfgang Wick1,9, Matthia A Karreman1,9, Frank Winkler1,9. 1. Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 2. Edinger Institute, Institute of Neurology, University of Frankfurt am Main, Frankfurt am Main, Germany. 3. German Cancer Research Center DKFZ Heidelberg, Germany and German Cancer Consortium DKTK partner site, Frankfurt/Mainz Germany. 4. Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany. 5. Tumour Cell Biology Laboratory, The Francis Crick Institute, London, UK. 6. Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Frankfurt am Main, Germany. 7. Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. 8. Department of Dermatology, Medical Faculty and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany. 9. Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
Abstract
BACKGROUND: Brain metastases (BM) are a frequent complication of malignant melanoma (MM), with limited treatment options and poor survival. Prevention of BM could be more effective and better tolerated than treating established BM in various conditions. METHODS: To investigate the temporospatial dynamics of PI3K/Akt/mTOR (PAM) pathway activation during BM formation and the preventive potential of its inhibition, in vivo molecular imaging with an Akt biosensor was performed, and long-term intravital multiphoton microscopy through a chronic cranial window in mice. RESULTS: In vivo molecular imaging revealed invariable PAM pathway activation during the earliest steps of brain colonization. In order to perform a long-term intravascular arrest and to extravasate, circulating MM cells needed to activate their PAM pathway during this process. However, the PAM pathway was quite heterogeneously activated in established human brain metastases, and its inhibition with the brain-penetrant PAM inhibitor GNE-317 resulted in only modest therapeutic effects in mice. In contrast, giving GNE-317 in preventive schedules that included very low doses effectively reduced the growth rate and number of BM in two MM mouse models over time, and led to an overall survival benefit. Longitudinal intravital multiphoton microscopy found that the first, rate-limiting steps of BM formation-permanent intravascular arrest, extravasation, and initial perivascular growth-are most vulnerable to dual PI3K/mTOR inhibition. CONCLUSION: These findings establish a key role of PAM pathway activation for critical steps of early metastatic brain colonization and reveal its pharmacological inhibition as a potent avenue to prevent the formation of clinically relevant BM.
BACKGROUND: Brain metastases (BM) are a frequent complication of malignant melanoma (MM), with limited treatment options and poor survival. Prevention of BM could be more effective and better tolerated than treating established BM in various conditions. METHODS: To investigate the temporospatial dynamics of PI3K/Akt/mTOR (PAM) pathway activation during BM formation and the preventive potential of its inhibition, in vivo molecular imaging with an Akt biosensor was performed, and long-term intravital multiphoton microscopy through a chronic cranial window in mice. RESULTS: In vivo molecular imaging revealed invariable PAM pathway activation during the earliest steps of brain colonization. In order to perform a long-term intravascular arrest and to extravasate, circulating MM cells needed to activate their PAM pathway during this process. However, the PAM pathway was quite heterogeneously activated in established human brain metastases, and its inhibition with the brain-penetrant PAM inhibitor GNE-317 resulted in only modest therapeutic effects in mice. In contrast, giving GNE-317 in preventive schedules that included very low doses effectively reduced the growth rate and number of BM in two MM mouse models over time, and led to an overall survival benefit. Longitudinal intravital multiphoton microscopy found that the first, rate-limiting steps of BM formation-permanent intravascular arrest, extravasation, and initial perivascular growth-are most vulnerable to dual PI3K/mTOR inhibition. CONCLUSION: These findings establish a key role of PAM pathway activation for critical steps of early metastatic brain colonization and reveal its pharmacological inhibition as a potent avenue to prevent the formation of clinically relevant BM.
Authors: Alexandra S Zimmer; Seth M Steinberg; Dee Dee Smart; Mark R Gilbert; Terri S Armstrong; Eric Burton; Nicole Houston; Nadia Biassou; Brunilde Gril; Priscilla K Brastianos; Scott Carter; David Lyden; Stanley Lipkowitz; Patricia S Steeg Journal: Future Oncol Date: 2020-04-09 Impact factor: 3.404
Authors: Yvonne Kienast; Louisa von Baumgarten; Martin Fuhrmann; Wolfgang E F Klinkert; Roland Goldbrunner; Jochen Herms; Frank Winkler Journal: Nat Med Date: 2009-12-20 Impact factor: 53.440
Authors: Dejan Juric; Filip Janku; Jordi Rodón; Howard A Burris; Ingrid A Mayer; Martin Schuler; Ruth Seggewiss-Bernhardt; Marta Gil-Martin; Mark R Middleton; José Baselga; Douglas Bootle; David Demanse; Lars Blumenstein; Karl Schumacher; Alan Huang; Cornelia Quadt; Hope S Rugo Journal: JAMA Oncol Date: 2019-02-14 Impact factor: 31.777
Authors: Matthias Osswald; Jonas Blaes; Yunxiang Liao; Gergely Solecki; Miriam Gömmel; Anna S Berghoff; Laurent Salphati; Jeffrey J Wallin; Heidi S Phillips; Wolfgang Wick; Frank Winkler Journal: Clin Cancer Res Date: 2016-08-12 Impact factor: 12.531
Authors: Cristina Saura; Johanna Bendell; Guy Jerusalem; Shaun Su; Qinhua Ru; Stefan De Buck; David Mills; Sophie Ruquet; Ana Bosch; Ander Urruticoechea; Joseph T Beck; Emmanuelle Di Tomaso; David W Sternberg; Cristian Massacesi; Samit Hirawat; Luc Dirix; Jose Baselga Journal: Clin Cancer Res Date: 2014-01-27 Impact factor: 12.531
Authors: Sagun Parakh; John J Park; Shehara Mendis; Rajat Rai; Wen Xu; Serigne Lo; Martin Drummond; Catherine Rowe; Annie Wong; Grant McArthur; Andrew Haydon; Miles C Andrews; Jonathan Cebon; Alex Guminski; Richard F Kefford; Georgina V Long; Alexander M Menzies; Oliver Klein; Matteo S Carlino Journal: Br J Cancer Date: 2017-05-18 Impact factor: 7.640
Authors: Ayal A Aizer; Nayan Lamba; Manmeet S Ahluwalia; Kenneth Aldape; Adrienne Boire; Priscilla K Brastianos; Paul D Brown; D Ross Camidge; Veronica L Chiang; Michael A Davies; Leland S Hu; Raymond Y Huang; Timothy Kaufmann; Priya Kumthekar; Keng Lam; Eudocia Q Lee; Nancy U Lin; Minesh Mehta; Michael Parsons; David A Reardon; Jason Sheehan; Riccardo Soffietti; Hussein Tawbi; Michael Weller; Patrick Y Wen Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Shuncong Wang; Yuanbo Feng; Lei Chen; Jie Yu; Chantal Van Ongeval; Guy Bormans; Yue Li; Yicheng Ni Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942